IUC26700-80

Abstract Code: IUC26700-80   Outcomes of dual immunotherapy versus other first line treatments for metastatic renal carcinoma Woods 1, S. Growcott 1, A. Gee 1 (1) Royal United Hospital, Bath – United Kingdom   Background: The Checkmate trial...

IUC26699-97

Abstract Code: IUC26699-97   Who Gets Left Out? The Real-World Eligibility Gap in Landmark Metastatic Renal Cell Carcinoma Trials Zeb 1 (1) university Hospital Birmingham – United Kingdom   Who Gets Left Out? The Real-World Eligibility Gap in Landmark...

IUC26697-95

Abstract Code: IUC26697-95 First Line Tyrosine Kinase Inhibitors (TKIs) in metastatic Renal Cell Cancer (mRCC)- A regional cancer Centre experience. Gul 1, O. Oghenevwede 2, E. Fetherston 1, O. Shahin 1, K. Kumar 2 (1) Freeman Hospital, Newcastle upon Tyne –...

IUC26695-93

Abstract Code: IUC26695-93   Real-world Outcomes of First-line Immune Checkpoint Inhibitor–Tyrosine Kinase Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: A Regional Cancer Centre Experience Gul 1, E. Fetherston 1, O. Oghenevwede 2, O. Shahin 3,...

IUC26694-92

Abstract Code: IUC26694-92   Stereotactic Body Radiotherapy and Immunotherapy for Metastatic Renal Cell Carcinoma Croatian Uro-Oncology Network Experience Brcic 1, J. Murgic 1, K. Brcic 2, M. Lekic 3, I. Tomaskovic 4, M. Jazvic 1, D. Schwarz 3, M. Penc 5, T....
error: Content is protected !!